RA0686

antibody from Oursmab

Targeting: SIRPA BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0686

Provider

Oursmab

Product name

Epacmarstobart (Biosimilar Reference Antibody) (SIRPA)

Antibody type

Monoclonal

Description

Epacmarstobart (development codes FSI-189 and GS-0189) is an investigational, chimeric humanized immunoglobulin G1 kappa (IgG1¦Ê) monoclonal antibody being developed for cancer immunotherapy. It represents a novel immunomodulatory approach by targeting a key regulatory receptor on myeloid cells. Unlike T-cell checkpoint inhibitors, its mechanism of action is centered on modulating the phagocytic activity of macrophages. By binding to its target, Signal Regulatory Protein Alpha (SIRP¦Á), on macrophages, epacmarstobart blocks a critical "don't eat me" signal, thereby unleashing the ability of macrophages to engulf and destroy cancer cells.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.